Mairal, Carmen Cintora , Martin-Gutierrez, Guillermo , Rodriguez-Villodres, Angel , Cisneros, Jose Miguel , Lepe, Jose Antonio , de la Rosa, Jose Manuel Ortiz
No
Antibiotics (Basel)
Article
Científica
09/05/2025
001495888900001
2-s2.0-105006709792
Background/Objectives: Meropenem is widely used to treat Pseudomonas aeruginosa infections; however, the pathogen's increasing resistance compromises its efficacy. In this study, we aimed to develop a selective culture medium for detecting the presence of meropenem-resistant Pseudomonas aeruginosa in respiratory specimens within 24 h. Methods: The medium's performance was challenged using a collection of 130 clinical Pseudomonas aeruginosa strains (of which 85 were meropenem-susceptible, 14 were meropenem-intermediate, and 21 were meropenem-resistant). Subsequently, clinical validation was carried out using 130 respiratory samples. Results: The selective medium demonstrated excellent sensitivity (average 98.7%) and specificity (average 90%) across bacterial concentrations ranging from 1 x 104 to 1 x 108 CFU/mL, and a high negative predictive value (average 99.2%) compared to the broth microdilution (BMD) method. Clinical validation with bronchoalveolar lavage (BAL) and tracheobronchial aspirate (TBA) clinical specimens (N = 130) revealed a strong performance, with 92,3% categorical agreement. Conclusions: This method accelerates susceptibility testing, is user-friendly, and delivers reliable results, contributing to the optimization of empirical treatment for respiratory tract infections.
meropenem; empiric treatment;